Similar articles

• Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.

  Yokosuka O. Yokosuka O. J Gastroenterol. 2004 Aug;39(8):813-4. doi: 10.1007/s00535-004-1415-9. J Gastroenterol. 2004. PMID: 15338383 No abstract available.
• Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.

  Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ. Chan HL, et al. J Med Virol. 2002 Oct;68(2):182-7. doi: 10.1002/jmv.10185. J Med Virol. 2002. PMID: 12210406
• Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation.

  Trautwein C. Trautwein C. J Hepatol. 2004 Sep;41(3):362-9. doi: 10.1016/j.jhep.2004.06.013. J Hepatol. 2004. PMID: 15336437 Review. No abstract available.
• [Effects of lamivudine and interferon-alpha combination therapy on chronic hepatitis B].

  Tang Y, Chen G, Zheng R. Tang Y, et al. Zhonghua Gan Zang Bing Za Zhi. 2002 Apr;10(2):89. Zhonghua Gan Zang Bing Za Zhi. 2002. PMID: 11983118 Chinese. No abstract available.
• Management of hepatitis B after renal transplantation: an update.

  Fabrizi F, Lunghi G, Poordad FF, Martin P. Fabrizi F, et al. J Nephrol. 2002 Mar-Apr;15(2):113-22. J Nephrol. 2002. PMID: 12018626 Review.